<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <!-- Font Awesome -->
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.9.0/css/all.min.css"
        integrity="sha512-q3eWabyZPc1XTCmF+8/LuE1ozpg5xxn7iO89yfSOd5/oKvyqLngoNGsx8jq92Y8eXJ/IRxQbEC+FGSYxtk2oiw=="
        crossorigin="anonymous" referrerpolicy="no-referrer" />
    <!-- Bootstrap CSS -->
    <link rel="stylesheet" href="css/bootstrap.min.css">
    <!-- Custom CSS -->
    <link rel="stylesheet" href="css/style.css">
</head>

<body class="position-fixed">

    <div class="main_page5">
        <div class="nav_orange">
            <div class="nav_orange_left">
                <h4 class="GothamBook mb-0"><strong>Hajek et al. INSIGHT-MM and RMG Real-world study:</strong> <br> a global prospective analysis of Ixazomib (NINLARO) + Rd in RRMM<sup class="GothamLight">1</sup></h4>
            </div>
            <div class="nav_orange_right">
                <img src="img/logo_orange.png" alt="">
            </div>
        </div>
        <!-- page 5 middle box -->
            <div class="page5_middle_box page8_middle_box mb-3">
                <div class="page8_middle_left fs-14">
                    <h4 class="txt_orange GothamBook mt-1 mb-3">STUDY <strong class="GothamBold">DESIGN:</strong></h4>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-1 me-2" src="img/li_2.svg" alt=""> <span>An expanded pooled analysis of Ixazomib <br> (NINLARO) + Rd in patients with RRMM<sup>1</sup>:</span></p>
                    <p class="d-flex align-items-start dark_secondary GothamBook ps-4 mb-2"><img class="mt-1 me-2" src="img/li_1.svg" alt=""> INSIGHT-MM: a large, global, prospective, <br> Real-world study that enrolled >4300 patients <br> with RRMM</p>
                    <p class="d-flex align-items-start dark_secondary GothamBook ps-4 mb-2"><img class="mt-1 me-2" src="img/li_1.svg" alt=""> Czech Registry of Monoclonal Gammopathies (RMG)</p>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-1 me-2" src="img/li_2.svg" alt=""> <span>At data cut-off*, 263 patients (132 in INSIGHT-MM <br> and 131 in RMG) had been included; median <br> follow-up was 14.8 months<sup>1</sup></span></p>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-1 me-2" src="img/li_2.svg" alt=""> <span>Patients in these studies had received a median <br> of 2 prior lines vs a median of 1 prior therapy in <br> the TOURMALINE-MM1 study<sup>1,2</sup></span></p>
                </div>
                <div class="page8_middle_right fs-14">
                    <h4 class="txt_orange GothamBook mt-1 mb-3">STUDY <strong class="GothamBold">ENDPOINTS:</strong></h4>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-1 me-2" src="img/li_2.svg" alt=""> <span>Treatment effectiveness was evaluated <br> by best response to therapy, and through <br> assessment of DOT, TTNT, PFS, and OS<sup>1</sup></p>
                    <p class="d-flex align-items-start dark_secondary GothamBook mb-2"><img class="mt-1 me-2" src="img/li_2.svg" alt=""> <span>Safety was assessed by recording dose <br> reductions and discontinuations of Ixazomib <br> (NINLARO) or lenalidomide, and the <br> reasons for these events during the study period<sup>1</sup></p>
                </div>
            </div>
            <div class="page5_middle_box page8_middle_box_p mb-1">
                <p class="GothamBook dark_secondary fs-11 justify mb-0"><span class="fs-11">Study limitations:</span> Real-world analyses are often non-randomized, observational, retrospective studies that may have <br>
                    unobserved treatment selection biases as well as other limitations that should be considered when comparing results <br>
                    with clinical trials. Outcomes should be interpreted with caution due to small sample size, limited follow-up, and limited <br>
                    maturity of data. Many of the patients included in the analysis were treated at academic centres; therefore, these results <br>
                    may not be representative of the community practice setting.</p>
            </div>
        <!--  -->
            <div class="page5_middle_box pt-3 mb-4">
                <div class="page5_btns_sm">
                    <a href="../page22/index.html" class="text-uppercase"><p class="mb-0 position-relative">PFS</p></a>
                    <a href="../page26/index.html" class="text-uppercase"><p class="mb-0 position-relative">ORR</p></a>
                    <a href="../page32/index.html" class="text-uppercase"><p class="mb-0 position-relative">SAFETY</p></a>
                    <a href="../page9/index.html" class="text-uppercase"><p class="mb-0 position-relative">PATIENT BASELINE CHARACTERISTICS</p></a>
                </div>
            </div>

            <div class="page5_middle_box page5_p_sm mb-3 pb-2 w-100" style="margin-top: 29px;">
                <p class="GothamLight">
                    *1 September 2019 for INSIGHT-MM, 5 February 2020 for RMG <br>
                    DOT = duration of therapy; MM = multiple myeloma; OS = overall survival; PFS = progression-free survival; Rd = REVLIMIDÂ® (lenalidomide) + dexamethasone; <br>
                    RRMM = relapsed/refractory multiple myeloma; RMG = Registry of Monoclonal Gammopathies; TTNT = time to next treatment.
                </p>
            </div>


            <div class="footer_page5">
                <div class="d-flex align-items-end">
                    <div class="page5_btns_md">
                        <a href="../page5/index.html"><p class="mb-0 position-relative">MM1 study design</p></a>
                        <a href="../page6/index.html"><p class="mb-0 position-relative">MM1 patient baseline characteristics</p></a>
                        <a href="../page8/index.html"><p class="mb-0 position-relative">RWE study Hajek et al.</p></a>
                        <a href="../page15/index.html"><p class="mb-0 position-relative">RWE study Terpos et al.</p></a>
                        <a href="../page11/index.html"><p class="mb-0 position-relative">RWE study Chari et al.</p></a>
                        <a href="../page18/index.html"><p class="mb-0 position-relative">RWE study Minarik et al.</p></a>
                        <a href="../page21/index.html"><p class="mb-0 position-relative">MM1 PFS</p></a>
                        <a href="../page23/index.html"><p class="mb-0 position-relative">MM1 PFS in patients with high-risk cytogenetics</p></a>
                        <a href="../page25/index.html"><p class="mb-0 position-relative">MM1 response rate</p></a>
                        <a href="../page28/index.html"><p class="mb-0 position-relative">MM1 PFS in <br> pre-treated patients</p></a>
                        <a href="../page31/index.html"><p class="mb-0 position-relative">MM1 safety data</p></a>
                        <a href="../page34/index.html"><p class="mb-0 position-relative">Dosing</p></a>
                        <a href="../page36/index.html"><p class="mb-0 position-relative">Summary</p></a>
                        <a href="../page38/index.html"><p class="mb-0 position-relative">MM6 data</p></a>
                        <a></a>
                    </div>
                    <div class="footer_inner_nav1 position-static ms-auto bg-transparent p-0">
                        <ul>
                            <li>
                                <a href="../page4/index.html"><img src="img/page_1_footer_icon_1.svg" alt=""></a>
                            </li>
                            <li>
                                <a href="https://onetakeda.app.box.com/s/reg7tviee8telgupc6cccshjet2wqqqh" target="_blank" class="text-uppercase">pi</a>
                            </li>
                            <li>
                                <a href="../page10/index.html" class="text-uppercase">ref</a>
                            </li>
                        </ul>
                    </div>
                </div>
            </div>
    </div>

</body>

</html>